A carregar...
Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma
Advances in the understanding of the biology of renal cell carcinoma have led to recent approval of several new agents including drugs that target vascular endothelial growth factor. Sunitinib is an oral tyrosine kinase inhibitor which interferes with multiple intracellular tumorogenic pathways, and...
Na minha lista:
Main Authors: | , , , |
---|---|
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
Dove Medical Press
2009
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2886329/ https://ncbi.nlm.nih.gov/pubmed/20616894 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|